Loading
Lingke Medical
Lingke Medical Technology (Hangzhou) Co., Ltd. (瓴科医疗) develops intravascular temperature-control products for stroke patients. It says no comparable product exists in China and aims to be the first domestic company to fill that gap. Its pitch is AI-based calculation for precise temperature control. It plans later to add remote monitoring and AI support for diagnosis, treatment plans and prognosis. The company was registered in January 2022 and says it holds 3 utility model patents and 1 invention patent. It is venture-backed according to PitchBook. I found no public figures on funding amounts, revenue or headcount.
Funding
Every round, secondary, debt facility or acquisition involving Lingke Medical that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—